YKL-40 is marker of mortality in hospitalized patients

November 20, 2012
YKL-40 is marker of mortality in hospitalized patients
For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the Journal of Internal Medicine.

(HealthDay)—For patients admitted to the hospital, the inflammatory biomarker YKL-40 is a strong predictor of mortality, regardless of diagnosis, according to a study published online Nov. 12 in the Journal of Internal Medicine.

In an effort to examine the of YKL-40 in an unselected patient population, Naja Dam Mygind, M.D., from Rigshospitalet in Copenhagen, Denmark, and colleagues analyzed from 1,407 consecutive acute patients (>40 years) admitted to hospital during a one-year period. Patients were followed for a median of 11.47 years.

The researchers found that, compared with healthy controls, median YKL-40 was significantly increased in patients (157 versus 40 µg/L). Compared with patients with YKL-40 in the lowest quartile, those with YKL-40 in the highest quartile had a significantly elevated hazard ratio (HR) for all-cause mortality in the first year (HR, 7.1) and in the total study period (HR, 3.4). Compared to patients with YKL-40 below the normal age-corrected 95-percentile, patients with YKL-40 above that level had a significantly increased risk of death (HRs, 2.1 after one-year and 1.5 during the total study period). Based on multivariate analysis, YKL-40 was an independent of mortality, which was most significant in the first year, and was a marker of in all disease categories. Independent of disease type, the HR for death was increased for those with YKL-40 above the 95th percentile, compared with healthy subjects.

"The level of YKL-40 at admission is a strong predictor of overall mortality, independent of diagnosis, and could be useful as a biomarker in the acute evaluation of all patients," the authors write.

One author is listed on a European patent relating to YKL-40. Quidel provided some of the YKL-40 assay kits.

Explore further: Statin use at cancer diagnosis linked to lower mortality

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Statin use at cancer diagnosis linked to lower mortality

November 8, 2012
(HealthDay)—For patients with cancer, statin use prior to diagnosis correlates with reduced all-cause and cancer-related mortality, according to a study published in the Nov. 8 issue of the New England Journal of Medicine.

Glucose levels at admission predict death in pneumonia

May 30, 2012
(HealthDay) -- For patients with community-acquired pneumonia without preexisting diabetes, serum glucose levels at admission are predictive of death at 28 and 90 days, according to a study published online May 29 in BMJ.

Long-term mortality risk low after cerebral vein thrombosis

July 12, 2012
(HealthDay) -- For patients who survive a cerebral vein thrombosis (CVT), the long-term risk of mortality and recurrent venous thromboembolism (VTE) seems to be low, according to a study published in the July issue of the ...

Recommended for you

New insights into protein's role in inflammatory response

July 28, 2017
A protein called POP2 inhibits a key inflammatory pathway, calming the body's inflammatory response before it can become destructive, Northwestern Medicine scientists have demonstrated in mouse models.

Targeting 'broken' metabolism in immune cells reduces inflammatory disease

July 12, 2017
The team, led by researchers at Imperial College London, Queen Mary University of London and Ergon Pharmaceuticals, believes the approach could offer new hope in the treatment of inflammatory conditions like arthritis, autoimmune ...

A perturbed skin microbiome can be 'contagious' and promote inflammation, study finds

June 29, 2017
Even in healthy individuals, the skin plays host to a menagerie of bacteria, fungi and viruses. Growing scientific evidence suggests that this lively community, collectively known as the skin microbiome, serves an important ...

Inflammatory bowel disease: Scientists zoom in on genetic culprits

June 28, 2017
Scientists have closed in on specific genes responsible for Inflammatory Bowel Disease (IBD) from a list of over 600 genes that were suspects for the disease. The team from the Wellcome Trust Sanger Institute and their collaborators ...

Trials show unique stem cells a potential asthma treatment

June 28, 2017
A study led by scientists at Monash University has shown that a new therapy developed through stem cell technology holds promise as a treatment for chronic asthma.

Researchers find piece in inflammatory disease puzzle

May 23, 2017
Inflammation is the process by which the body responds to injury or infection but when this process becomes out of control it can cause disease. Monash Biomedicine Discovery Institute (BDI) researchers, in collaboration with ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.